The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Year:
      2019
    • Author-Supplied Keywords:
      Breast cancer
      Cost-effectiveness
      Economic evaluation
      EndoPredict
      Gene expression
      Risk of recurrence
    • Abstract:
      Highlights • Few studies have explored the role of EndoPredict in the treatment of breast cancer. • This study considers the role of EndoPredict in an indeterminate risk treatment group. • EndoPredict is expected to not be cost-effective but with significant uncertainty. Abstract Background Adjuvant chemotherapy in breast cancer patients post resection has been estimated to reduce mortality rates by up to 30%. However, the heterogeneous nature of the disease and patients implies that not all patients should receive the treatment. Many existing prognostic tools, may not definitively estimate the most effective treatment strategy, resulting in an indeterminate risk classification. In such cases gene expression profiling tests can aid the treatment decision. Methods This study evaluated the cost-effectiveness of EndoPredict in patients with indeterminate risk classification. A mathematical model was constructed to determine how the change in treatment decisions impacted the long term health of the population, and the future cost implications to the NHS. Results EndoPredict was found to lead to 36.9% of patients having a change in treatment decision. As a result its use was found to result in an increase in population health but also in total costs, resulting in an incremental cost-effectiveness ratio of £26,836 per quality adjusted life year. This was subject to significant parametric and structural uncertainty. Conclusion While EndoPredict was found to be more expensive overall, its ability to affect a more optimal allocation of chemotherapy, resulted in long term health gains, however, they were insufficient to justify the high cost of EndoPredict. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Health Policy & Technology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      22118837
    • Accession Number:
      135428094
  • Citations
    • ABNT:
      HINDE, S. et al. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy & Technology, [s. l.], v. 8, n. 1, p. 75, 2019. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=135428094. Acesso em: 24 out. 2020.
    • AMA:
      Hinde S, Theriou C, May S, et al. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy & Technology. 2019;8(1):75. Accessed October 24, 2020. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=135428094
    • APA:
      Hinde, S., Theriou, C., May, S., Matthews, L., Arbon, A., Fallowfield, L., & Bloomfield, D. (2019). The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy & Technology, 8(1), 75.
    • Chicago/Turabian: Author-Date:
      Hinde, Sebastian, Chloi Theriou, Shirley May, Lucy Matthews, Amy Arbon, Lesley Fallowfield, and David Bloomfield. 2019. “The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Health Policy & Technology 8 (1): 75. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=135428094.
    • Harvard:
      Hinde, S. et al. (2019) ‘The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer’, Health Policy & Technology, 8(1), p. 75. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=135428094 (Accessed: 24 October 2020).
    • Harvard: Australian:
      Hinde, S, Theriou, C, May, S, Matthews, L, Arbon, A, Fallowfield, L & Bloomfield, D 2019, ‘The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer’, Health Policy & Technology, vol. 8, no. 1, p. 75, viewed 24 October 2020, .
    • MLA:
      Hinde, Sebastian, et al. “The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Health Policy & Technology, vol. 8, no. 1, Mar. 2019, p. 75. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=135428094.
    • Chicago/Turabian: Humanities:
      Hinde, Sebastian, Chloi Theriou, Shirley May, Lucy Matthews, Amy Arbon, Lesley Fallowfield, and David Bloomfield. “The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Health Policy & Technology 8, no. 1 (March 2019): 75. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=135428094.
    • Vancouver/ICMJE:
      Hinde S, Theriou C, May S, Matthews L, Arbon A, Fallowfield L, et al. The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy & Technology [Internet]. 2019 Mar [cited 2020 Oct 24];8(1):75. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=135428094